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Abstract 
 
Background: All-trans retinoic acid (RA) is known to regulate keratinocyte proliferation and 
differentiation and retinoids are used as therapeutic agents in certain dermatological disorders 
(e.g. psoriasis, acne). Epidermal expression of the heparin-binding EGF-like growth factor 
(HB-EGF) is induced by RA treatment and HB-EGF is responsible for RA-mediated 
epidermal hyperplasia in vivo. RA also induces HB-EGF expression in cultured keratinocytes 
and alters their differentiating phenotype. R115866 is a specific inhibitor of the cytochrome 
P450 isoform CYP26, which is involved in the metabolic inactivation pathway of RA. 
Thereby, R115866 is thought to be able to increase the intracellular levels of endogenous RA.  
Objectives: To determine whether R115866 potentiates the effect of RA at low concentrations 
on keratinocytes. 
Methods: We analyzed HB-EGF, involucrin and keratin 10 mRNA and protein levels in 
autocrine human keratinocyte cultures incubated for 18h with RA or R115866 alone and with 
RA and R115866 combinations.  
Results: RA induces HB-EGF and involucrin expression in a concentration-dependent 
manner, whereas it inhibits keratin 10. R115866 alone has no effect on the expression of these 
genes. However when R115866 is combined with low concentrations of RA, we observe 
inductions of the expression of HB-EGF and involucrin.  
Conclusion: These results strongly suggest that R115866 potentiates the effects of RA on 
epidermal keratinocytes when RA is present at low concentrations. 
 
215 words 
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Introduction 
 
All-trans retinoic acid (RA) is an indispensable natural regulator of epidermal proliferation 
and differentiation and retinoids are used as therapeutic agents for the treatment of 
dermatological disorders such as psoriasis, acne or skin aging [1]. These compounds exert 
their biological activity through binding with transcription-regulatory factors, the retinoic acid 
receptors (RAR,  and ) and the retinoic X receptors (RXR ,  and ). Only RAR, 
RAR, RXR and RXR are expressed in the epidermis [2]. Although studies of the effects 
of RA on epidermal differentiation have sometimes produced controversial results when 
obtained in vivo or in vitro [1], it appeared that inducing or inhibiting effects can depend also 
on the differentiation markers analyzed [3]. Particularly in autocrine high cell density cultures 
of epidermal keratinocytes, RA markedly inhibits the mRNA and protein expression of the 
suprabasal keratin 10 (K10), an early marker of epidermal differentiation, whereas RA 
induces both mRNA and protein levels of involucrin, a later marker especially expressed in 
upper spinous and granular layers in the differentiated normal epidermis in vivo [3]. Besides 
effects on epidermal differentiation, RA is also able to induce keratinocyte proliferation and 
thus epidermal hyperplasia. Recent studies have shown that this phenomenon is due to an 
induction by RA of the heparin-binding EGF-like growth factor (HB-EGF) [4, 5], a potent 
stimulator of keratinocyte proliferation and migration which belongs to the epidermal growth 
factor (EGF) family and which can be induced by stress conditions in keratinocytes [6]. 
Because RA has profound effects on epidermal growth and differentiation, there is a tight 
homeostatic control of its level in tissues like the epidermis due to RA inactivation by 
cytochrome P450 (CYP) isozyme system(s). The isozyme CYP26 is particularly involved as 
RA is the only recognized substrate of CYP26 [7]. Recently, CYP26 was detected in human 
skin, principally in the epidermal basal layer, and RA was shown to be an inducer of CYP26 
expression in normal cultured keratinocytes [8].  
R115866 (talarozole or RambazoleTM; Barrier Therapeutics, Geel, Belgium) is a specific 
inhibitor of CYP26 and induces, when delivered in vivo, an increase in tissue levels of 
endogenous RA by blocking RA catabolism [9, 10]. Thus, R115866 increases RA in plasma 
and skin, exerting cutaneous effects that have also been described with retinoids [9]. Recently, 
clinical trials have started to demonstrate the efficacy of R115866 in the treatment of psoriasis 
and acne [10-12]. R115866 (third generation retinoic acid metabolism blocking agents or 
RAMBAs)  is a nanomolar (IC50=4nM) inhibitor of CYP26-dependent RA conversion and is 
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about three orders of magnitude more powerful than liarozole (IC50=3µM) (first RAMBAs 
generation) which lacked CYP isozyme specificity [9].  
In this study, we have taken advantage of the unique environmental conditions obtained 
during autocrine growth of epidermal keratinocytes because in such conditions the expression 
of epidermal differentiation markers has been thoroughly characterized in total absence of 
serum or of other sources of exogenous factors, and because this model is thus also totally 
devoid of any source of vitamin A [3,13]. We analyzed the effects of RA, R115866, and RA 
in combination with R115866 in autocrine cultures of normal human epidermal keratinocytes. 
All experiments described here were performed at the cell confluent state which is 
characterized by cell growth arrest and initiation of the commitment towards differentiation. 
These conditions are very likely uniquely suited for the identification of subtle regulations of 
differentiation. We focused on HB-EGF, involucrin and keratin 10 gene expression and 
observed that, contrarily to RA, R115866 alone is unable to induce any modification in the 
expression of those genes. However, when R115866 is combined with RA at low 
concentration (10-9 M), the expression of both HB-EGF and involucrin is increased, whereas 
Keratin 10 gene expression is inhibited, very similarly to the effects obtained with a ten-fold 
higher concentration of RA (10-8 M). 
Together, our data show that the CYP26 inhibitor R115866 potentiates the effect of 
nanomolar concentrations of RA on the differentiation process in epidermal keratinocytes. 
 
 
Materials and Methods 
 
Antibodies and chemicals 
 
Rabbit polyclonal anti-ERK1/2 antibody was obtained from Upstate (Millipore, Brussels, 
Belgium) and goat anti-human HB-EGF antibody was from R&D Biosciences (Abingdon, 
UK). Rabbit anti-human involucrin antibody was purchased from Harbor Bio-products 
(Boechout, Belgium). Mouse anti-human keratin10 antibody was from Dako (Heverlee, 
Belgium). Rabbit anti-human EGFR antibody was purchased from Cell Signaling (Leiden, 
The Netherlands) and rabbit anti-human phosphor-EGFR Tyr1173 antibody was from 
Biosource (Nivelles, Belgium). Mouse anti-human HER2 and rabbit anti-human phosphor-
HER2 came from Cell Signaling (Leiden, The Netherlands). Retinoic acid was purchased 
from Sigma-Aldrich (Bornem, Belgium) and R115866 is from Barrier Therapeutics (Geel, 
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Belgium). Keratinocyte growth medium (KGM2) came from Lonza (Verviers, Belgium). 
Keratinocyte complete culture medium (Epilife and HKGS) and keratinocyte autocrine 
medium (Epilife) were from Cascade Biologics (Manfield, UK). AEC, glycergel and 
horseradish peroxydase (HRP)-conjugated anti-rabbit were obtained from Dako (Heverlee, 
Belgium). 
 
Cell culture and treatment 
 
Normal human keratinocytes were isolated by the trypsin float technique [14] from adult skin 
samples obtained at plastic surgery (Dr Bienfait, Clinique St. Luc, Namur-Bouge, Belgium). 
Primary cultures were initiated in complete keratinocyte growth medium (KGM2). 
Proliferating primary cultures were trypsinized and keratinocytes were plated into secondary 
cultures at 6x103 cells per cm2 in complete culture medium (Epilife containing HKGS). When 
the cells covered approximately 40% of the culture substratum, keratinocytes were switched 
into an autocrine medium (Epilife alone) which does not contain any growth factor or serum. 
In such conditions, keratinocytes proliferate autonomously until the confluence of the culture 
is reached concomitantly with cell growth arrest [3,13,14]. All experiments were performed 
exactly at confluence. Autocrine keratinocyte cultures were treated 18 h with RA 
(concentrations ranging from 10-9 to 10-6 M) or R115866 (concentrations ranging from 10-9 to 
10-6 M) before analysis. 
 
Stratified cultures of keratinocytes 
 
For the production of reconstructed human epidermis (RHE), we used our previous published 
method [15]. Briefly, second- to third-passage proliferating keratinocytes were collected and 
plated at high density on polycarbonate cultures inserts with 0.4 µm diameter pore size 
(Millipore) in Epilife medium containing HKGS and 1.5 mM CaCl2. After 24h, the 
keratinocytes were exposed to the air-liquid interface and we used a medium Epilife 
containing HKGS, 1.5 mM calcium, 50 µg/ml vitamin C and 10ng/ml KGF to feed the cells 
from the bottom of the polycarbonate filter. Every 2 days, this medium was renewed and the 
RHE was treated after 11 days with RA (concentrations ranging from 10-9 to 10-6M) or 
R115866 (concentrations ranging from 10-9 to 10-6M) during 2 days. 
 
Total RNA isolation and Real-time PCR 
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Total RNA were extracted by the RNeasy kit (Qiagen, Hilden, Germany)) and then reverse 
transcribed into cDNA by the Super Script II RNase H-reverse transcriptase kit (Invitrogen, 
Merelbeke, Belgium). Power SYBR Green PCR Master Mix (Applied Biosystems, Lennik, 
Belgium) was used for the Real-Time PCR. Genes were normalized to the gene 36B4 [16]. 
The primers sense and anti-sense (300nM, Sigma-Aldrich, Bornem, Belgium) sequences 
were: for 36B4 sense 5’-ATCAACGGGTACAAACGAGTC-3’, 36B4 anti-sense 5’-
CAGATGGATCAGCCAAGAAGG-3’, HB-EGF sense 5’-TGGCCCTCCACTCCTCATC-
3’, HB-EGF anti-sense 5’-GGGTCACAGAACCATCCTAGCT-3’, for involucrin sense 5’-
TGAAACAGCCAACTCCAC-3’, involucrin anti-sense 5’-TTCCTCTTGCTTTGATGGG-3’, 
keratin 10 sense 5’AATCAGATTCTCAACCTAACAAC-3’ and keratin 10 anti-sense 5’-
CTCATCCAGCACCCTACG-3’.   
 
Protein extraction and Western blotting 
 
Before lysis, keratinocytes were washed with PBS and then scraped into twice concentrated 
Laemmli sample buffer (Tris-HCl 62.5mM, SDS 2%, glycerol 8.7%, bromophenol blue 
0.05%, DTT 0.2%).  Thereafter, the proteins extracted were analyzed by SDS-polyacryamide 
gel electrophoresis (PAGE) and transferred onto PVDF membranes (GE Healthcare Bio-
sciences, Uppsala, Sweden). The membranes were blocked with PBS/Tween20 (0.1%) 
containing 5% powdered milk, before incubating with specific primary antibodies. After three 
washing steps, the membranes were incubated with HRP-conjugated secondary antibodies 
(Dako, Hervelee, Belgium). Finally, chemoluminescent detection was realized by using BM 
Chemoluminescence Blotting Substrate (Roche Diagnostics, Mannheim, Germany). The 
detection of ERK protein as described previously [17] is used as a loading control. 
 
Measurement of the release of HB-EGF 
 
Release of HB-EGF in the culture medium was quantified by ELISA using the DuoSet ELISA 
human HB-EGF kit from R&D systems (Abingdon, UK). The optical density was determined 
at 540 nm (wavelength correction at 450 nm) using a microplate reader (Molecular devices, 
Sunnyvale, CA). 
 
Immunohistochemical labelling of reconstructed human epidermis sections 
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After the respective treatments, the RHE were washed with PBS, separated from the inserts 
and immediately embedded in optimal cutting temperature (OCT) compound. Frozen sections 
(6 µm thick) of RHE were made with a cryostat and fixed in 4% paraformaldehyde for 15 
minutes followed by washes in 0.1 M glycine. In order to inhibit endogenous peroxidases, 
every tissue section was incubated in 3% H2O2 for 10 minutes, then blocked and 
permeabilized in PBS containing 0.1% BSA and 0.02% Triton X-100. After the blocking step, 
all sections were incubated for 1 hour with appropriate primary antibody diluted in 
PBS/BSA/Triton X-100 (mouse anti-human K10 antibody). All slides were then washed with 
PBS and for keratin 10 immunolabelling the sections were then incubated with HRP-
secondary antibody (Vectastain ABC kit, Vector Laboratories, Burlingame, CA). Detection of 
HRP was performed with AEC Substrate-Chromogen and counterstaining with hemalun was 
done for 5 minutes. All slides were mounted in glycergel for observation in an Olympus 
AX70 microscope. 
 
Results 
 
RA treatment dose-dependently alters HB-EGF, involucrin and keratin 10 gene 
expression whereas R115866 does not    
 
Autocrine cultures of human epidermal keratinocytes were studied at confluence when they 
initiate differentiation [3] and treated for 18h with either RA or R115866 at concentrations 
ranging from 10-9M to 10-6M. Observation of the cultures by phase-contrast microscopy 
revealed no alteration in morphology of the keratinocytes treated with each of both 
compounds at all the tested concentrations (data not shown). We then analyzed by 
quantitative RT-PCR the mRNA expression of HB-EGF, as well as of involucrin and keratin 
10, respectively late and early markers of epidermal differentiation. Our results confirm that 
RA treatment upregulates dose-dependently HB-EGF [4] and involucrin gene expression, 
whereas keratin 10 is downregulated (Fig 1) [3]. In parallel, we observed that in the absence 
of RA, after 18h of treatment, the CYP26 inhibitor R115866 has no effect by itself on HB-
EGF, involucrin or keratin 10 gene expression in confluent cultured keratinocytes (Fig 1).  
These effects of RA or R115866 alone were also investigated at the protein level. Protein 
extracts from autocrine confluent keratinocytes in culture were analyzed by Western blot. As 
shown in Figure 2a, RA dose-dependently induces HB-EGF protein expression, whereas no 
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effect of treatment with R115866 at any of the tested concentrations is observed on HB-EGF 
protein expression. The results of this representative experiment correlate properly with the 
HB-EGF mRNA expression by keratinocytes shown in Figure 1 and reveal again that 
R115866 has no effect on HB-EGF per se in culture conditions where RA is absent.  
HB-EGF is synthesized as a transmembrane protein that can be cleaved enzymatically to 
release a soluble growth factor (mature HB-EGF) which can bind and activate the EGF 
receptor (EGFR) or indirectly activate the EGF receptor 2 (HER2). Thus, in order to 
determine if HB-EGF is released in our model, we measured HB-EGF by ELISA in the 
culture media after treatments. We found some release of HB-EGF in good accordance with 
its production (Fig 2b). Indeed, 10-6M RA induces the highest release of HB-EGF (75 pg/ml). 
In order to explore whether the release of HB-EGF is able to activate receptors, we analyzed 
after 18h of RA or R115866 treatment the tyrosine phosphorylation of EGFR and HER2 (Fig 
3). The results suggest that the release of HB-EGF is probably too weak in order to stimulate 
detectable phosphorylation of both receptors. However, De Potter et al. have shown that the 
activation of HER2 in keratinocytes depends on the state of differentiation [18], and found 
that heregulin can activate HER2, probably through HER3, two days after reaching 
confluence. Thus, in our model studied at confluence, the activation of HER2 (and HER3, 
data not shown) cannot be observed in the cultured keratinocytes, maybe because these cells 
are not yet in a receptive phenotype in our assay. 
We also used Western blot analysis in order to confirm the effect of RA or R115866 on 
keratin 10 and involucrin differentiation markers: RA treatment significantly upregulated 
involucrin and reduced keratin 10 protein expression in perfect accordance with the mRNA 
expression (Fig 3). R115866 alone has no effect on the expression of these proteins. 
 
 
R115866 combined with RA alters the RA-induced changes in gene expression of 
epidermal keratinocytes 
 
R115866 acts as an inhibitor of the CYP26-mediated metabolism of RA and therefore 
R115866 treatment enhances the intracellular levels of endogenous RA [9]. This enhancement 
is impossible in autocrine culture conditions since, in absence of serum, there is no 
endogenous RA in the culture medium. This can explain the absence of effect of R115866 
when the compound is added alone as in Figure 1. Thus, in order to investigate the effects of a 
combination of R115866 with RA at low concentrations, R115866 at concentrations ranging 
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from 10-9M up to 10-6M was added to the culture medium containing RA at low 
concentrations (10-9M or 10-8M). Then, we analyzed the mRNA levels as above by 
quantitative RT-PCR. Figure 4a illustrates the HB-EGF, involucrin and keratin 10 mRNA 
expression patterns after 18h of exposure of autocrine cultures of human keratinocytes with 
R115866 combined with 10-9M RA. Compared with RA alone, a significant increase in the 
expression of both HB-EGF and involucrin is observed when R115866 concentration 
increases (Fig 4a). Since R115866 prevents the breakdown of RA, sustained effective cellular 
concentrations of RA are likely responsible for the enhanced effects due to the combinations 
of RA with R115866. Accordingly, the downregulation of keratin 10 gene expression after a 
treatment of R115866 (10-9M) combined with 10-9M RA suggests that the intracellular 
concentration of RA remains high enough in order to inhibit additionally the keratin 10 
mRNA expression (Fig 4a).  
Similarly, a treatment with R115866 combined with RA at 10-8M was also performed (Fig 
4b). Although the highest R115866 concentration applied (10-6M) induces a significant 
enhancement in the mRNA expression level for HB-EGF, the lower concentrations do not 
induce a statistically significant enhancement. This is probably due to the substantial 
induction already produced by 10-8M RA in the expression of HB-EGF at this concentration. 
Similarly, R115866 combined with 10-8M RA does not induce further involucrin gene 
expression. Surprisingly, one can observe an increase due to R115866, but the level remains 
below the level induced by 10-8M RA alone. Also, as RA at this concentration highly inhibits 
keratin 10 mRNA expression, the addition of R115866 is unable to inhibit further the 
expression level of this marker. 
The protein expression of HB-EGF in cellular extracts prepared from keratinocytes treated 
with the combination of R115866 and RA was analyzed by Western blot and a representative 
experiment is illustrated in Figure 5a. R115866 at increasing concentrations combined with 
10-9M RA upregulates the HB-EGF protein expression (Fig 5a), in perfect accordance with 
the HB-EGF mRNA analysis performed in the same conditions (Fig 4a). However, when 
studying keratinocytes treated with 10-8M RA, a concentration that already strongly induces 
the expression of HB-EGF (Fig 2a), the combination with R115866 at 10-9M or 10-8M 
concentrations does not increase this expression, contrarily to the highest concentrations (10-
7M and 10-6M) of R115866 which seem to increase the detection of HB-EGF.  
To investigate the shedding of HB-EGF after R115866 combined with RA, we collected the 
culture media and measured HB-EGF by ELISA. It is interesting to notice that the profile of 
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HB-EGF release is parallel with its protein production (Fig 5b). The ELISA analysis shows 
that 10-9M RA induces a weak release of HB-EGF (35 pg/ml), and when R115866 is 
combined with 10-9M RA, we observed an upregulation of HB-EGF concentration in the 
medium (65 pg/ml). On the other hand, we observed as in Figure 5a that 10-9M and 10-8M 
R115866 combined with 10-8M RA treatment does not increase the shedding of HB-EGF (Fig 
5b). 
Again, the shedding of HB-EGF is insufficient to induce the phosphorylation of EGFR and 
HER2 (Fig 6). We found also that keratin 10 is downregulated after 10-9 M RA treatment 
compared to the control. We observed that this expression decreases with the addition of 
R115866 at the highest concentrations (10-7M and 10-6M). Similarly, when we compared the 
RA treatment (10-8M) and the combination of R155866 and 10-8M RA, we observed that 
R115866 strongly downregulates the expression of keratin 10 (Fig 6). After 10-8 RA 
treatment, the involucrin expression is mainly induced and thus, as learned from RT-PCR 
analysis, no upregulation happens when R115866 is added (Fig 6). 
Altogether, our results demonstrate that, during 18h incubation, R115866 has no effect on 
human epidermal keratinocytes in total absence of RA. Rather they show that R115866 
potentiates the effect of RA at a concentration that is too low (10-9M) to strongly alter the 
gene expression of these cells. This potentiation effect was also observed when R115866 was 
combined with RA at 10-10M concentration (data not shown). When RA is present at a 
concentration high enough to induce by itself effects on keratinocytes (i.e. 10-8M), any 
potentiation by R115866 becomes more and more difficult to detect. 
 
The effects of RA and R115866 treatments can be extended to reconstructed human 
epidermis (RHE). 
Since the discrepancy between retinoids action in human monolayers cultures and human skin 
in vivo is well known [1], we wondered whether similar effects of RA or R115866 and the 
combination between R115866 and RA could be observed within the reconstructed human 
epidermis (RHE) [15].  
The immunolabelling of keratin 10 revealed that in suprabasal cell layers, mainly just above 
the basal keratinocytes layer (Fig 7a, arrows), keratin 10 is strongly expressed in the Ctl and 
DMSO conditions or after R115866 (10-6M) treatment (Fig 7a). After RA treatment, we 
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observed that keratin 10 expression is reduced in this layer mainly at a 10-6M RA. Keratin 10 
was also reduced after R115866 (10-6M) combined with RA (10-9 M) (Fig 7a).  
The immunolabelling of involucrin was also performed, but revealed no variation between the 
different conditions (data not shown). Of course, after 7 days of culture, keratinocytes are well 
differentiated in the RHE model and have already expressed involucrin before the treatment. 
Thus, it seems impossible to show any variation in involucrin protein expression between the 
different culture conditions. 
These variations between the results obtained with the RHE and the autocrine culture of 
keratinocytes might likely be explained also by other differences in culture conditions: in the 
RHE model, although the culture is serum-free, the medium contains growth factors and 
vitamin C which are necessary in order to obtain a well differentiated stratified epithelium. 
Particularly, growth factors can interfere with expression of differentiation markers [13]. 
Thus, our data illustrate that, in order to identify regulation of epidermal differentiation, a 
keratinocytes monolayer model in autocrine conditions allows a very precise analysis of 
differentiation markers gene expression. Our data also suggest that fine regulations are more 
difficult to observe in a more complex model of epidermal differentiation. 
 
Discussion 
 
Retinoids are used as therapy for many skin diseases such as psoriasis and acne. They are 
important regulators of epidermal proliferation and differentiation. However the effects of RA 
obtained in vivo or in vitro on epidermal proliferation or differentiation are sometimes 
contradictory [1], but it appeared that it can depend on the differentiation markers analyzed 
and on the culture conditions [3, 19]. Here, we first confirm that addition of RA to the 
autocrine culture medium of confluent keratinocyte cultures induces a diminution of keratin 
10 mRNA expression, whereas the expression of involucrin is upregulated [3]. We further 
confirm that the epidermal expression of HB-EGF is also highly induced by the treatment of 
these cells with RA [4]. 
The cellular metabolic inactivation of RA (which is initiated by hydroxylation) is carried out 
mainly by an isozyme of the cytochrome P450 system, specifically CYP26, and RA is 
apparently the main substrate for CYP26 [9]. R115866 is a highly specific and potent CYP26 
inhibitor, thus inhibiting in particular the catabolism of RA [9]. Therefore, R115866 can 
enhance the tissue levels of endogenous RA and thereby is able to produce biological effects 
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similar to those of retinoids in several experimental assays [9], but also in clinical treatments 
of psoriasis and acne [10,12]. 
The unique autocrine culture model of keratinocytes, which means culture in a chemically-
defined medium without addition of any peptide exogenous factor or serum (and consequently 
without RA), allows a precise study of keratinocyte responses to R115866 either in the 
absence or presence of RA, added at well-defined concentrations. In the present study, we 
have shown that addition of R115866 alone to the medium of confluent keratinocyte cultures 
performed in autocrine conditions has no effect on HB-EGF, involucrin and keratin 10 gene 
expressions in these cells. However, R115866 combined with RA at 10-9M concentration 
increases HB-EGF and involucrin expression, and concomitantly decreases keratin 10 
expression (Figs 4 and 5). These results suggest intracellular elevation of RA concentration 
when compared with cultures treated with RA alone (Figs 1 and 2). When R115866 at 10-6M 
is combined with 10-8M RA, the RA-induced upregulation of HB-EGF is further upregulated, 
but no significant alteration of the RA effect on involucrin and keratin 10 gene expression is 
observed, probably due to the significant effects already obtained with RA alone at the 10-8M 
concentration.  
We have observed that RA treatment or treatment with R115866 combined with RA induce 
HB-EGF released (Figs 2 and 5), however EGFR and HER2 were not phosphorylated in our 
experimental conditions. This can be due to the internalization of the receptor (and 
degradation) induced upon ligand-binding, or alternatively this can be the consequence that 
the EGFR activation does not last enough in order to be still detectable after 18h of treatment. 
Indeed, we have clearly observed that, after 1h of RA treatment, the EGFR is activated (data 
not shown).  
We have also analyzed the effects of RA or R115866, as well as the effects of R115866 
combined with RA, on loricrin and filagrin gene expression and we found no alteration of 
theses genes expression (data not shown). This is not surprising since all experiments have 
been performed at confluence state, which is characterized by cell growth-arrest and 
commitment to early differentiation, whereas loricrin and filagrin are only expressed in the 
granular and cornified layer in the epidermis. Although treatment with RA and treatment with 
the combination of R115866 with retinoic acid have large effects on differentiation (keratin 
10 and involucrin), consequences depend on the differentiation markers analyzed in the study.  
In conclusion, our results clearly show that during an 18h incubation R115866 exerts effects 
on the expression of specific differentiation markers in epidermal keratinocytes by its ability 
to prevent the degradation of RA. Indeed, R115866 enhances the effects of low concentrations 
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of RA, producing effects similar to those obtained at higher concentrations of RA. This 
demonstration that R115866 is acting on keratinocytes through RA may explain, at least 
partially, recent clinical data which have revealed the efficacy of R115866 in the treatment of 
psoriasis and acne [10,12]. 
The effects of RA, R115866 and the combination between RA and R115866 on a model of 
reconstructed human epidermis (RHE) have been investigated. The immunolabelling of 
keratin 10 shows similar results compared to the results obtained with keratinocyte 
monolayers. The effects producing a decreased expression of keratin 10 is localized to the 
immediate suprabasal layer, where the neo-synthesis of keratin 10 is strongly induced 
upwardly moving keratinocytes. However, contrarily to Hsia et al. [20] who show a complete 
decrease of the keratin 10 expression in the RHE model treated with topical application of 
retinoids for 3 days, we do not observe such a strong disappearance of the keratin 10 protein.  
It appears that the model used for the study of the effects of RA or R115866 on markers of 
differentiation can produce particular data due to the state of differentiation in the model.   
Thus, in order to identify regulation of differentiation, a monolayer model in autocrine 
conditions allows a precise analysis of differentiation markers gene expression at a crucial 
phenotypical state. Our results obtained with the RHE suggest that fine regulations are more 
difficult to observe in a more complex model.  
Altogether, our results suggest that the autocrine culture model of keratinocytes is very 
adequate for the precise study of RA effects on this cell type. They also show that R115866, a 
specific inhibitor of CYP26 isozyme, has no effect on epidermal keratinocytes in absence of 
RA, but when RA is added at low concentrations R115866 is apparently able to maintain the 
endogenous concentration of this retinoid at a relevant level, thereby resulting into an 
enhanced retinoid activity. Thus, R115866 potentiates the effects of RA on normal epidermal 
keratinocytes. 
 
 
 
References  
 
[1] Fisher GJ, Voorhees JJ. Molecular mechanisms of retinoid actions in skin. FASEB J 
1996; 10: 1002-13. 
 
 14 
[2]  Chapellier B, Mark M, Messaddeq N et al. Physiological and retinoid-induced 
proliferations of epidermis basal keratinocytes are differently controlled. EMBO J 2002; 
21: 3402-13. 
 
[3]  Poumay Y, Herphelin F, Smits P et al. High-cell-density phorbol ester and retinoic acid 
upregulate involucrin and downregulate suprabasal keratin 10 in autocrine cultures of 
human epidermal keratinocytes. Mol Cell Biol Res Commun 1999; 2: 138-44. 
 
[4]  Stoll SW, Elder JT. Retinoid regulation of heparin-binding EGF-like growth factor gene 
expression in human keratinocytes and skin. Exp Dermatol 1998; 7: 391-7. 
 
[5]  Rittie L, Varani J, Kang S et al. Retinoid-induced epidermal hyperplasia is mediated by 
epidermal growth factor receptor activation via specific induction of its ligands heparin-
binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol 2006; 126: 
732-9. 
 
[6]  Mathay C, Giltaire S, Minner F et al. Heparin-binding EGF-like growth factor is 
induced by disruption of lipids rafts and oxidative stress in keratinocytes and 
participates in the epidermal response to cutaneous wounds. J Invest Dermatol 2008; 3: 
717-27. 
 
[7]  Ray WJ, Bain G, Yao M, Gottlieb DI. CYP26, a novel mammalian cytochrome P450, is 
induced by retinoic acid and defines a new family. J Biol Chem 1997; 272: 18702-08. 
 
[8]  Heise R, Mey J, Neis MM et al. Skin retinoid concentrations are modulated by 
CYP26AI expression restricted to basal keratinocytes in normal human skin and 
differentiated 3D skin models. J Invest Dermatol 2006; 126: 2473-80. 
 
[9]  Stoppie P, Borgers M, Borghgraef P et al. R115866 inhibits all-trans-retinoic acid 
metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000; 293: 
304-12. 
 
[10] Verfaille C, Thissen C, Bovenschen H et al. Oral R115866 in the treatment of moderate 
to severe plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007; 21: 1038-46. 
 
[11] Bovenschen HJ, Otero ME, Langewouters AM et al. Oral retinoic acid metabolism 
blocking agent Rambazole for plaque psoriasis: an immunohistochemical study. Br J 
Dermatol 2007; 156: 263-70. 
  
[12] Verfaille CJ, Coel M, Boersma IH et al. Oral R115866 in the treatment of moderate to 
severe facial acne vulgaris: an exploratory study. Br J Dermatol 2007; 157: 122-6. 
 
[13] Poumay Y, Pittelkow MR. Cell density and culture factors regulate keratinocyte 
commitment to differentiation and expression of suprabasal K1/K10 keratins. J Invest 
Dermatol 1995; 104: 271-6. 
 
[14] Wille JJ, Jr., Pittelkow MR, Shipley GD, Scott RE. Integrated control of growth and 
differentiation of normal human prokeratinocytes cultured in serum-free medium: clonal 
analyses, growth kinetics, and cell cycle studies. J Cell Physiol 1984; 121: 31-44. 
 
 15 
[15] Poumay Y, Dupont F, Marcoux S et al. A simple reconstructed human epidermis: 
preparation of the culture model and utilization in in vitro studies. Arch Dermatol Res 
2004; 296: 203-11. 
 
 [16] Laborda J. cDNA used as an estradiol-independent mRNA control is the cDNA for 
human acidic ribosomal phosphoprotein PO. Nucleic Acis Res 1991; 19: 3998. 
 
[17]  Jans R, Atanasova G, Jadot M, Poumay Y. Cholesterol depletion upregulates involucrin 
expression in epidermal keratinocytes through activation of p38. J Invest Dermatol 
2004; 123 :564-73. 
 
[18] De Potter Y, Poumay Y, Squillace K, Pittelkow M. Human EGF receptor (HER) family 
and heregulin members are differentially expressed in epidermal keratinocytes and 
modulate differentiation. Exp Cell Res  2001;271: 315-28. 
 
[19] Bernard F-X, Pedretti N, Rosdy M, Deguercy A. Comparison of gene expression profiles 
in human keratinocyte mono-layer cultures, reconstructed epidermis and normal human 
skin; transcriptional effects of retinoid treatments in reconstructed human epidermis. 
Exp Dermatol 2002; 11: 59-74 
 
[20] Hsia E, Johnston MJ, Houden RJ et al. Effects of topically applied acitretin in 
reconstructed human epidermis and the rhino mouse. J Invest Dermatol 2008; 128: 125-
30. 
 
 
 
Acknowledgements 
 
We gratefully thank Dr Bienfait (Clinique St Luc, Bouge) for providing the normal skin 
samples and Professor Eric Depiereux (URBM, University of Namur) for his help with the 
statistical analysis (ANOVA). SG is holding a research fellowship from FRIA (Belgium). 
This research received support from FRFC grant 2.4506.01 and FNRS grant 1.5.033.06F to 
YP.  
 
 
Conflict of interest 
 
PS is a former employee of Barrier Therapeutics. 
 
 
 
Figures 
 
 
 16 
Fig 1: RA treatment alters HB-EGF, involucrin and keratin 10 gene expression, whereas 
R115866 has no effect. 
Confluent keratinocyte cultures were treated for 18h with increasing RA or R115866 
concentrations ranging from 10-9M to 10-6M. Total RNA were extracted and reverse-
transcribed into cDNA before analysis by Real-Time PCR in order to determine HB-EGF ( ), 
 17 
involucrin ( ) or keratin 10 ( ) gene expression (normalized to 36B4). Data represent three 
independent experiments and were analyzed by ANOVA I after testing the homogeneity of 
variance (Bartlett). Post-hoc comparisons were performed by pairwise Scheffe’s test. Error 
bars represent  2 SEM (Standard Error of the Mean) with Student’s correction for variance 
estimation. To ensure homosedasticity, values for keratin 10 expression (x) were replaced by 
their logarithmic values (log (x)). 
 
Fig 2: HB-EGF protein expression is induced by RA but not by R115866 treatment. 
(a) Confluent keratinocyte cultures were left untreated (Ctl) or treated 18h with increasing RA 
or R115866 concentrations ranging from 10-9 to 10-6M. After treatment, proteins were 
extracted and analyzed by Western blotting. Detection of the total ERK proteins was used as a 
loading control. The results shown are representative data obtained in three independent 
experiments. (b) The culture media were harvested and analyzed by ELISA to measure the 
concentration of HB-EGF released after 18h of RA treatment or R115866. The results shown 
represent mean values of two experiments. 
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Fig 3: Western blot analysis of keratin 10 and involucrin expression, and analysis of EGFR 
phosphorylation. 
Confluent keratinocyte cultures were left untreated (Ctl) or treated 18h with increasing RA or 
R115866 concentrations ranging from 10-9 to 10-6M. After treatment, proteins were extracted 
and analyzed by Western blotting. Keratin 10 protein expression is reduced by RA but not by 
R115866 treatment whereas involucrin protein expression is upregulated. RA or R115866 
treatment does not induce the phosphorylation of EGFR or HER2. Detection of the total ERK 
proteins was used as a loading control. 
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Fig 4: Effect of R115866 in combination with RA (10-9 or 10-8M) on HB-EGF, involucrin and 
keratin 10 gene expression. 
Confluent keratinocyte cultures were treated for 18h with R115866 combined with RA at a 
concentration 10-9M (a) or 10-8M (b). Total RNA extracts were reverse-transcribed into cDNA 
and analyzed by Real-Time PCR to determine HB-EGF ( ), involucrin ( ) or keratin 10 ( ) 
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gene expression. Data represent three independent experiments and were analyzed by 
ANOVA I after testing the homogeneity of variance (Bartlett). Post-hoc comparisons were 
performed by pairwise Scheffe’s test. Error bars represent  2 SEM (Standard Error of the 
Mean) with Student’s correction for variance estimation.  
 
Fig 5: R115866 combined with RA treatment (10-9 or 10-8M) increases HB-EGF protein 
expression. 
Confluent keratinocyte cultures were left untreated (Ctl) or treated for 18h with R115866 
combined with RA at 10-9M or 10-8M concentration. (a) Proteins were then extracted and 
analyzed by Western blot. Detection of total ERK protein was used as a loading control. The 
results shown are representative data obtained in three independent experiments. (b) The 
culture media were harvested and analyzed by ELISA to measure the concentration of HB-
EGF released after 18h of RA treatment or R115866. The results shown represent mean 
values of two experiments. 
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Fig 6: R115866 potentiates the effect of RA on keratin 10 and involucrin expression.  
Confluent keratinocyte cultures were left untreated (Ctl) or treated for 18h with R115866 
combined with RA at 10-9M or 10-8M concentration. After treatment, proteins were extracted 
and analyzed by Western blotting. Keratin 10 protein expression is reduced by R115866 
combined with RA (10-9M or 10-8M) treatment, whereas involucrin protein expression is 
upregulated. The combination of R115866 with RA treatment does not modify the 
phosphorylation of EGFR or HER2. Detection of the total ERK proteins was used as a 
loading control. 
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Fig 7: Effect of R115866 and RA on keratin 10 expression in RHE. 
At the eleventh days of culture, the RHE were treated during 48h with RA (10-9M or 10-6M) 
or R115866 (10-6M) or R115866 (10-6M) combined with RA (10-9M). Then, histological 
sections perpendicular to the surface of RHE were prepared for the immunohistochemical 
detection of keratin 10. Arrowheads indicate where a decreased labeling of keratin 10 is 
observed after RA or after R115866 (10-6M) combined with RA (10-9M) treatment. Bars = 
25µm. 
 
 
